Zymeworks INC Schedule 13G passive stakes

Perceptive Advisors LLC and Joseph Edelman have reported a 5.4% beneficial ownership stake in Zymeworks Inc. via a Schedule 13G filing.

Rubric Capital Management LP and David Rosen have disclosed a 7.68% beneficial ownership stake in Zymeworks Inc., totaling 5,750,000 common shares.

Morgan Stanley has filed an amended Schedule 13G, reporting its beneficial ownership in Zymeworks Inc. has fallen to 3.4%.

Biotechnology Value Fund and its affiliates have increased their aggregate beneficial ownership in Zymeworks Inc. to 5.2% of outstanding common stock as of September 30, 2025.

Redmile Group, LLC and its principal, Jeremy C. Green, have disclosed a 4.9% beneficial ownership stake in Zymeworks Inc., totaling 3,705,750 shares.

Redmile Group, LLC and its principal Jeremy C. Green have disclosed a 5.6% beneficial ownership stake in Zymeworks Inc. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% in Zymeworks Inc.'s common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, disclosing their beneficial ownership in Zymeworks Inc., with Morgan Stanley Capital Services LLC's stake falling below the 5% reporting threshold.

Redmile Group, LLC and its affiliates have disclosed a passive 7.0% beneficial ownership stake in Zymeworks Inc., holding 4,840,463 common shares as of December 31, 2024.